|
1
|
Miyashiro I, Furukawa H, Sasako M,
Yamamoto S, Nashimoto A, Nakajima T, Kinoshita T, Kobayashi O and
Arai K: Gastric Cancer Surgical Study Group in the Japan Clinical
Oncology Group: Randomized clinical trial of adjuvant chemotherapy
with intraperitoneal and intravenous cisplatin followed by oral
fluorouracil (UFT) in serosa-positive gastric cancer versus
curative resection alone: final results of the Japan Clinical
Oncology Group trial JCOG9206-2. Gastric Cancer. 14:212–218. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Emoto S, Kitayama J, Ishigami H, Yamaguchi
H and Watanabe T: Clinical significance of cytological status of
peritoneal lavage fluid during intraperitoneal chemotherapy for
gastric cancer with overt peritoneal dissemination. Ann Surg Oncol.
22:780–786. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chua TC, Morris DL, Saxena A, Esquivel J,
Liauw W, Doerfer J, Germer CT, Kerscher AG and Pelz JO: Influence
of modern systemic therapies as adjunct to cytoreduction and
perioperative intraperitoneal chemotherapy for patients with
colorectal peritoneal carcinomatosis: a multicenter study. Ann Surg
Oncol. 18:1560–1567. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Elias D, Gilly F, Boutitie F, Quenet F,
Bereder JM, Mansvelt B, Lorimier G, Dubè P and Glehen O: Peritoneal
colorectal carcinomatosis treated with surgery and perioperative
intraperitoneal chemotherapy: retrospective analysis of 523
patients from a multicentric French study. J Clin Oncol. 28:63–68.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ishigami H, Kitayama J, Kaisaki S,
Hidemura A, Kato M, Otani K, Kamei T, Soma D, Miyato H, Yamashita
H, et al: Phase II study of weekly intravenous and intraperitoneal
paclitaxel combined with S-1 for advanced gastric cancer with
peritoneal metastasis. Ann Oncol. 21:67–70. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Elias D, Glehen O, Pocard M, Quenet F,
Goéré D, Arvieux C, Rat P and Gilly F: Association Française de
Chirurgie: A comparative study of complete cytoreductive surgery
plus intraperitoneal chemotherapy to treat peritoneal dissemination
from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann
Surg. 251:896–901. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL,
Cheng FL, Zhou YF, Xiong B, Yonemura Y and Li Y: Cytoreductive
surgery and hyperthermic intraperitoneal chemotherapy improves
survival of patients with peritoneal carcinomatosis from gastric
cancer: final results of a phase III randomized clinical trial. Ann
Surg Oncol. 18:1575–1581. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kapala M, Meterissian S and Schricker T:
Neuraxial anesthesia and intraoperative bilevel positive airway
pressure in a patient with severe chronic obstructive pulmonary
disease and obstructive sleep apnea undergoing elective sigmoid
resection. Reg Anesth Pain Med. 34:69–71. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chua TC, Morris DL and Esquivel J: Impact
of the peritoneal surface disease severity score on survival in
patients with colorectal cancer peritoneal carcinomatosis
undergoing complete cytoreduction and hyperthermic intraperitoneal
chemotherapy. Ann Surg Oncol. 17:1330–1336. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yamaguchi H, Kitayama J, Ishigami H, Emoto
S, Yamashita H and Watanabe T: A phase 2 trial of intravenous and
intraperitoneal paclitaxel combined with S-1 for treatment of
gastric cancer with macroscopic peritoneal metastasis. Cancer.
119:3354–3358. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Franko J, Ibrahim Z, Gusani NJ, Holtzman
MP, Bartlett DL and Zeh HJ III: Cytoreductive surgery and
hyperthermic intraperitoneal chemoperfusion versus systemic
chemotherapy alone for colorectal peritoneal carcinomatosis.
Cancer. 116:3756–3762. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Diéras V, Guastalla JP, Ferrero JM, Curé
H, Weber B, Winckel P, Lortholary A, Mayer F, Paraiso D, Magherini
E, et al: A multicenter phase II study of cisplatin and docetaxel
(Taxotere) in the first-line treatment of advanced ovarian cancer:
A GINECO study. Cancer Chemother Pharmacol. 53:489–495. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kitayama J, Ishigami H, Yamaguchi H and
Watanabe T: Salvage gastrectomy after intravenous and
intraperitoneal paclitaxel (PTX) combined with oral
tegafur/gimeracil/oteracil potassium (S-1) for gastric cancer with
peritoneal metastasis. Eur J Surg Oncol. 40:S342014. View Article : Google Scholar
|
|
14
|
Lee AW, Tyrer JP, Doherty JA, Stram DA,
Kupryjanczyk J, Dansonka-Mieszkowska A, Plisiecka-Halasa J,
Spiewankiewicz B, Myers EJ, Chenevix-Trench G, et al: Australian
Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study
Group: Evaluating the ovarian cancer gonadotropin hypothesis: a
candidate gene study. Gynecol Oncol. 136:542–548. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Che YL, Luo SJ, Li G, Cheng M, Gao YM, Li
XM, Dai JM, He H, Wang J, Peng HJ, et al: The C3G/Rap1 pathway
promotes secretion of MMP-2 and MMP-9 and is involved in serous
ovarian cancer metastasis. Cancer Lett. 359:241–249. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hung SW, Marrache S, Cummins S, Bhutia YD,
Mody H, Hooks SB, Dhar S and Govindarajan R: Defective hCNT1
transport contributes to gemcitabine chemoresistance in ovarian
cancer subtypes: overcoming transport defects using a nanoparticle
approach. Cancer Lett. 359:233–240. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang J, Yang H, Li W, Xu H, Yang X and Gan
L: Thioredoxin 1 upregulates FOXO1 transcriptional activity in drug
resistance in ovarian cancer cells. Biochim Biophys Acta.
1852:395–405. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bakrin N, Classe JM, Pomel C, Gouy S,
Chene G and Glehen O: Hyperthermic intraperitoneal chemotherapy
(HIPEC) in ovarian cancer. J Visc Surg. 151:347–353. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Helm CW: Current status and future
directions of cytoreductive surgery and hyperthermic
intraperitoneal chemotherapy in the treatment of ovarian cancer.
Surg Oncol Clin N Am. 21:645–663. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Parson EN, Lentz S, Russell G, Shen P,
Levine EA and Stewart JH IV: Outcomes after cytoreductive surgery
and hyperthermic intraperitoneal chemotherapy for peritoneal
surface dissemination from ovarian neoplasms. Am J Surg.
202:481–486. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ohashi N, Jinno S, Kobayashi D, Tanaka C,
Yamada S, Fujii T, Nomoto S, Fujiwara M, Takeda S and Kodera Y:
Intravenous and intraperitoneal paclitaxel combined with S-1 for
advanced gastric cancer with peritoneal metastasis. Nihon Shokaki
Geka Gakkai Zasshi. 45:1137–1143. 2012.(In Japanese). View Article : Google Scholar
|
|
22
|
Gupta D and Lis CG: Role of CA125 in
predicting ovarian cancer survival - a review of the
epidemiological literature. J Ovarian Res. 2:132009. View Article : Google Scholar : PubMed/NCBI
|
